---
figid: PMC9647096__JCTH-11-207-g002
pmcid: PMC9647096
image_filename: JCTH-11-207-g002.jpg
figure_link: /pmc/articles/PMC9647096/figure/JCTH-D-22-00255-f2/
number: Fig. 2
figure_title: Regulatory pathway and possible targets of ferroptosis in HCC
caption: ABCC5, ATP-binding cassette subfamily C member 5; ACSL4, acyl-CoA synthetase
  long-chain family member 4; ALOXE3, arachidonate lipoxygenase 3; ATF4, Activating
  transcription factor 4; CISD1, CDGSH iron sulfur domain 1; DAZAP1, deleted in azoospermia
  associated protein 1; FTH1, ferritin heavy chain 1; GABPB1-AS1, GA-binding protein
  transcription factor subunit beta-1 antisense RNA 1; GPX4, glutathione peroxidase
  4; GSH, glutathione; GSTZ1, glutathione S-transferase zeta 1; HCC, hepatocellular
  carcinoma, IDH2, isocitrate dehydrogenase 2; Keap 1, kelch-like ECH-associated protein
  1; MT-1G, metallothionein-1G; NRF2, nuclear factor E2-related factor 2; PRDX5, peroxiredoxin-5;
  QSOX1, quiescin sulfhydryl oxidase 1; Rb, retinoblastoma; ROS, reactive oxygen species;
  SLC3A2, solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member
  11; S1R, Sigma 1 receptor; TAZ, transcriptional coactivator with PDZ-binding motif;
  TEAD, transcriptional enhanced associate domain; UBA1, ubiquitin-like modifier activating
  enzyme 1; YAP, Yes-associated protein.
article_title: 'Ferroptosis: From Basic Research to Clinical Therapeutics in Hepatocellular
  Carcinoma.'
citation: Ziyue Huang, et al. J Clin Transl Hepatol. 2023 Feb 28;11(1):207-218.
year: '2023'

doi: 10.14218/JCTH.2022.00255
journal_title: Journal of Clinical and Translational Hepatology
journal_nlm_ta: J Clin Transl Hepatol
publisher_name: XIA & HE Publishing Inc.

keywords:
- Hepatocellular carcinoma
- Ferroptosis
- Sorafenib
- Cancer therapy
- Molecular targets

---
